Functional analysis of Rb2/p130 interaction with cyclins

Department of Microbiology-Immunology, Jefferson Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Cancer Research (Impact Factor: 9.28). 06/1996; 56(9):2003-8.
Source: PubMed

ABSTRACT The retinoblastoma (Rb) family consists of the tumor suppressor pRb and related proteins p107 and pRb2/p130. Ectopic expression of pRb and p107 results in a growth arrest of sensitive cells in the G1 phase of the cell cycle. We demonstrated here that the growth-suppressive properties of pRb2/p130 were also specific for the G1 phase. The A-, E-, and D-type cyclins as well as transcription factor E2F1 and the E1A viral oncoprotein were able to rescue the pRb2/p130-mediated G1 growth arrest in SAOS-2 cells. The rescue with cyclins A and E correlated with their physical interaction with pRb2/p130, which surprisingly has been found to occur over all phases of the cell cycle. The phosphorylation status as well as the kinase activity associated with pRb2/p130 dramatically increased near the G1-S-phase transition. This suggests that, like the other Rb family members, pRb and p107, the phosphorylation of pRb2/p130 is controlled by the cell cycle machinery and that pRb2/p130 may indeed be another key G1-S-phase regulator.

Download full-text


Available from: Marco G Paggi, Aug 22, 2015
  • Source
    • "Indeed, it has been described that p130 undergoes phosphorylation at distinctive sites during the G0 phase in a way that characterizes p130 from the other members of the Rb family proteins (Kiess et al., 1995; Canhoto et al., 2000). p130 is phosphorylated by the Cdk4/Cyclin D or Cdk6/Cyclin D and Cdk2/Cyclin E or Cdk2/Cyclin A complexes and its expression levels fall when the cells enter into the S phase (Baldi et al., 1995; Mayol et al., 1995; Claudio et al., 1996; Dong et al., 1998; Tedesco et al., 2002). In vivo phosphorylation mapping of human p130 identified 22 serine and threonine residues, targeted by the kinases Cdk2, Cdk4 and Cdk6 (Hansen et al., 2001). "
    Retinoblastoma: An Update on Clinical, Genetic Counseling, Epidemiology and Molecular Tumor Biology, 03/2012; , ISBN: 978-953-51-0435-3
  • Source
    • "They share the ability to recruit chromatin-remodeling enzymes and their best characterized targets are the members of the E2F/DP family of transcription factors, generally referred to as E2F (Cinti et al., 2005; Tosi et al., 2005; Genovese et al., 2006; Macaluso et al., 2006; Purev et al., 2006). Both pRb2/p130 and p107 are able to bind cdk2/ cyclins A and E (Claudio et al., 1996). We have previously described the cdk2-dependent kinase inhibitory activity shown by the pRb2/p130 spacer domain, which suggests that part of its growth regulatory function could be mediated by the inhibition of this important cell cycle kinase (De Luca et al., 1997). "
    [Show abstract] [Hide abstract]
    ABSTRACT: One strategy in the development of anticancer therapeutics has been to arrest malignant proliferation through inhibition of the enzymatic activity of cyclin-dependent kinases (cdks), which are key regulatory molecules of the cell cycle. Over the past few years, numerous compounds with remarkable cdk inhibitory activity have been studied in cancer therapy, although it is very difficult to point out the best cdk to target. An excellent candidate appears to be cdk2, whose alteration is a pathogenic hallmark of tumorigenesis. The small molecule described in our study showed an inhibitory effect on the kinase activity of cdk2, a significant growth arrest observed in a colony formation assay and a reduction in the size of the tumor in nude mice, thus suggesting its potential role as a promising new type of mechanism-based antitumor drug, also for the treatment of hyperproliferative disorders.
    Oncogene 04/2007; 26(13):1829-39. DOI:10.1038/sj.onc.1209987 · 8.56 Impact Factor
  • Source
    • "Because of this, it is reasonable that pocket proteins, even overexpressed, could be extensively phosphorylated by specific cyclinicdk complexes, thus becoming functionally inactive in blocking the cell cycle. Conversely, pRb2/p130, which has been found coupled to cdk2 [Hannon et al., 1993; Claudio et al., 19961 could overcome p161NK4A homozygous deletion, bringing about effective growth inhibition. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Two genes, p107 and Rb2/p130, are strictly related to RB, the most investigated tumor suppressor gene, responsible for susceptibility to retinoblastoma. The products of these three genes, namely pRb, p107, and pRb2/p130 are characterized by a peculiar steric conformation, called "pocket," responsible for most of the functional interactions characterizing the activity of these proteins in the homeostasis of the cell cycle. The interest in these genes and proteins springs from their ability to regulate cell cycle processes negatively, being able, for example, to dramatically slow down neoplastic growth. So far, among these genes, only RB is firmly established to act as a tumor suppressor, because its lack-of-function is clearly involved in tumor onset and progression. It has been found deleted or mutated in most retinoblastomas and sarcomas, but its inactivation is likely to play a crucial role in other types of human cancers. The two other members of the family have been discovered more recently and are currently under extensive investigation. We review analogies and differences among the pocket protein family members, in an attempt to understand their functions in normal and cancer cells.
    Journal of Cellular Biochemistry 09/1996; 62(3):418-30. DOI:10.1002/(SICI)1097-4644(199609)62:3<418::AID-JCB12>3.0.CO;2-E · 3.37 Impact Factor
Show more